Highlights Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
9.525 ^USD	-5.60%		-5.13%	+4.33%

05-09	Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Phathom Pharmaceuticals Announces Voquezna® Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	02-13	CI
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	12-06	CI
Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? Tablets	11-28	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults	11-01	CI
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults	30/10/23	CI
Phathom Pharmaceuticals Seeks FDA Nod for Vonoprazan to Treat Non-Erosive GERD in Adults	26/09/23	MT
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany	26/09/23	CI
Phathom Pharmaceuticals Submits Six-Month Stability Data to US FDA Supporting Vonoprazan for Stomach Condition	21/08/23	MT
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Phathom Pharmaceuticals Sees Commercial Launch of Vonoprazan for Erosive Esophagitis, H. Pylori Indications in Q4	04/04/23	MT
Phathom Pharmaceuticals Provides Regulatory Update Following Its Recent Meeting with FDA Regarding the Complete Response Letters for Phathom's Erosive Esophagitis (EE) NDA and H. Pylori Post Approval Supplement to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK NDAs	04/04/23	CI
PHATHOM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	28/02/23	AQ
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	28/02/23	CI
Phathom Pharmaceuticals Says US FDA Asks for More Stability Data on Vonoprazan Products; Shares Plunge	10/02/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Highlights

Filters